Titan Pharmaceuticals announced the re-submission by Braeburn Pharmaceuticals of a New Drug Application (NDA) to the FDA for Probuphine, Titan’s...
Braeburn Pharmaceuticals presented data from the Phase III study of Probuphine (subdermal buprenorphine implant) for the long-term maintenance treatment of...
Titan Pharmaceuticals, Inc. announced that the FDA has approved Probuphine (buprenorphine) implant, the first product for the long-term maintenance treatment...
Braeburn Pharmaceuticals announces data from the Phase III study of Probuphine, a six month subdermal buprenorphine implant for the long-term...
Titan Pharmaceuticals, Inc. has announced that the majority of Psychopharmacologic Drugs Advisory Committee (PDAC) of the FDA members recognized the...
The Psychopharmacologic Drugs Advisory Committee (PDAC) of the FDA voted 12 to 5 in favour of approving Probuphine, from Titan...
Titan Pharmaceuticals, Inc. and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn...
Titan Pharmaceuticals, Inc. has announced that the European Commission ("EC") has approved Sixmo-buprenorphine, the brand name for Probuphine (buprenorphine) implant...
Titan Pharmaceuticals, Inc. announced that the FDA has notified Titan and its development and commercialization partner Braeburn Pharmaceuticals that it...